Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property
Guy A. Higgins, Nicole K. Carroll, Matthew A. Brown, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Lily R. Aleksandrova, Anthony G. Phillips
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 11, pp. 929-942
Closed Access | Times Cited: 161
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
Roger S. McIntyre, Angela T.H. Kwan, Rodrigo B. Mansur, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 21-32
Closed Access | Times Cited: 1
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective
John R. Kelly, Claire M. Gillan, Jack Prenderville, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 50
Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation
Gilly Wolf, Sandeep Singh, Karin Blakolmer, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 44-58
Closed Access | Times Cited: 36
Antidepressant- and anxiolytic-like activities and acute toxicity evaluation of the Psilocybe cubensis mushroom in experimental models in mice
Alberto Hernández-León, Raúl Iván Escamilla-Orozco, Aylín R. Tabal-Robles, et al.
Journal of Ethnopharmacology (2023) Vol. 320, pp. 117415-117415
Closed Access | Times Cited: 16
In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin
N. Jones, Laura M. Wagner, Molly C. Pellitteri Hahn, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 7
Psilocybin for the treatment of Alzheimer’s disease
Siyi Zheng, Rong Ma, Yang Yang, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 6
5-HT2A Receptor Knockout Mice Show Sex-Dependent Differences following Acute Noribogaine Administration
Sofía Villalba, Bruno González, Stephanie Junge, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 687-687
Open Access | Times Cited: 5
Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?
Kinga Sałaciak, Karolina Pytka
Pharmacology & Therapeutics (2021) Vol. 227, pp. 107872-107872
Open Access | Times Cited: 33
A systematic literature review of clinical trials and therapeutic applications of ibogaine
Patrick Köck, Katharina Froelich, Marc Walter, et al.
Journal of Substance Abuse Treatment (2021) Vol. 138, pp. 108717-108717
Open Access | Times Cited: 33
Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats
Piotr Popik, Adam S. Hogendorf, Ryszard Bugno, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1689-1703
Open Access | Times Cited: 22
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Seetal Dodd, Trevor R. Norman, Harris A. Eyre, et al.
CNS Spectrums (2022) Vol. 28, Iss. 4, pp. 416-426
Open Access | Times Cited: 22
Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders
Andreas B. Wulff, Charles D. Nichols, Scott M. Thompson
Neuropharmacology (2023) Vol. 231, pp. 109504-109504
Open Access | Times Cited: 14
A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond
Marco Pepe, Mohsen Hesami, Karla A. de la Cerda, et al.
Biotechnology Advances (2023) Vol. 69, pp. 108247-108247
Closed Access | Times Cited: 14
Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights
Salma Laabi, Claire LeMmon, Callie Vogel, et al.
International Immunopharmacology (2024) Vol. 130, pp. 111753-111753
Closed Access | Times Cited: 5
Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression
Magdalena Kolasa, Agnieszka Nikiforuk, Agata Korlatowicz, et al.
Psychopharmacology (2024)
Open Access | Times Cited: 5
Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice
Michael Noback, Johnny A. Kenton, Adam K. Klein, et al.
Neuropharmacology (2025), pp. 110334-110334
Closed Access
Dose-dependent changes in global brain activity and functional connectivity following exposure to psilocybin: a BOLD MRI study in awake rats
Evan Fuini, Arnold Chang, Richard J. Ortiz, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Cognitive and affective models of psychedelics in rodents
David J. Anderson, Emma Robinson
International review of neurobiology (2025)
Closed Access
Psychedelics: Science sabotaged by Social Media
Edward M. Sellers, Myroslava K. Romach
Neuropharmacology (2023) Vol. 227, pp. 109426-109426
Open Access | Times Cited: 10
Psychedelics action and schizophrenia
Marzena Maćkowiak
Pharmacological Reports (2023) Vol. 75, Iss. 6, pp. 1350-1361
Open Access | Times Cited: 10
Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders
Sheetal A. Raithatha, Jillian M. Hagel, Kaveh Matinkhoo, et al.
Journal of Medicinal Chemistry (2023) Vol. 67, Iss. 2, pp. 1024-1043
Open Access | Times Cited: 9
Effect of a single psilocybin treatment on Fos protein expression in male rat brain
Douglas Funk, Joseph A. Araujo, Malik Slassi, et al.
Neuroscience (2024) Vol. 539, pp. 1-11
Closed Access | Times Cited: 3
Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome
Valeria Buzzelli, Emilia Carbone, Antonia Manduca, et al.
Psychopharmacology (2022) Vol. 240, Iss. 1, pp. 137-147
Closed Access | Times Cited: 15
Effects of psilocybin, the 5-HT2A receptor agonist TCB-2, and the 5-HT2A receptor antagonist M100907 on visual attention in male mice in the continuous performance test
Arya Rahbarnia, Zhaoxia Li, Paul Fletcher
Psychopharmacology (2023)
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top